Table 1 Characteristics, management and outcome for levosimendan cases and non-levosimendan controls
Cases (“Levo”)a (n = 18) | Controlsb (n = 36) | P-value | Odds-Ratio | |
|---|---|---|---|---|
Patients characteristics | ||||
Age—median (IQR)—years | 61 (50–70) | 61,5 (52–68) | 0.63 | |
Female—No (%) | 15 (83.3) | 30 (83.3) | 1.00 | |
Arterial hypertension—No (%) | 6 (33.3) | 17 (47.2) | 0.39 | |
Smoking—No (%) | 10 (55.6) | 10 (27.8) | 0.07 | |
Diabetes—No (%) | 0 (0) | 1 (2.8) | 1.00 | |
Stroke history—No (%) | 2 (11.1) | 4 (11.1) | 1.00 | |
SAPS 2—median (IQR) | 60 (43; 65) | 49 (40; 57) | 0.15 | |
SOFA—median (IQR) | 8 (7; 11) | 6 (2; 9) | 0.03 | |
Characteristic of SAH | ||||
WFNS grade—median (IQR) | 5 (4; 5) | 4 (4; 5) | 0.43 | |
Fischer grade—median (IQR) | 4 (4; 4) | 4 (4; 4) | 0.48 | |
Coiling—No (%) | 16 (88.9) | 32 (88.9) | 1.00 | |
External ventricular drainage—No (%) | 7 (38.9) | 23 (63.9) | 0.09 | |
Decompressive craniectomy—No (%) | 2 (11.1) | 3 (8.3) | 1.00 | |
Cardiac impairmentc | ||||
Cardiac troponin peak—median (IQR)—ng/L | 3999 (2210; 7382) | 821 (40; 4532) | 0.007 | |
BNP peak—median (IQR)—ng/L | 1122 (762; 1718) | 138 (65; 937) | 0.001 | |
Outcome | ||||
Cerebral vasospasm—No (%) | 5 (27.8) | 24 (66.7) | 0.009 | 0.199 [0.0443; 0.766] |
Delayed cerebral ischemia—No (%) | 0 (0) | 7 (19.4) | 0.08 | NA |
MRS at 3 months ≤ 3—No (%) | 11 (61.1) | 18 (50) | 0.57 | 1.558 [0.4331; 5.922] |
Death at 3 months—No (%) | 1 (5.6) | 9 (25) | 0.14 | 0.181 [0.004; 1.516] |